预约演示
更新于：2026-01-11
Shanghai Shen Lian Biomedical Corp.
更新于：2026-01-11
概览
标签
感染
融合蛋白
疾病领域得分
一眼洞穿机构专注的疾病领域
技术平台
公司药物应用最多的技术
靶点
公司最常开发的靶点
关联
CN117567642
专利挖掘靶点 |
作用机制 |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段 |
首次获批国家/地区 |
首次获批日期 |
100 项与 申联生物医药（上海）股份有限公司 相关的临床结果
登录后查看更多信息
登录后查看更多信息
2025-12-01VETERINARY MICROBIOLOGY
Synthetic peptide vaccines targeting SVA elicit robust protective immune responses in swine
Article
作者: Yin, Bo ; Jiao, Mingjin ; Cao, Nan ; Liu, Shudan ; Li, Yamei ; Liu, Xiangzu ; Ji, Mingfang ; Qian, Ping ; Li, Xiangmin
Senecavirus A (SVA), an emerging pathogen in swine, causes vesicular disease with clinical manifestations similar to foot-and-mouth disease (FMD), vesicular stomatitis (VS), and swine vesicular disease (SVD), posing a significant economic threat to the global swine industry. Therefore, it is of vital importance to develop a safe and effective SVA vaccine. In this study, guided by the principles of synthetic biology, we designed and synthesized two SVA candidate synthetic peptides, TT-073 and TT-074, based on the highly conserved B-cell neutralizing epitope VP2150-160aa from the SVA capsid protein, and a helper T-cell epitope derived from the F protein of the urticaria virus. These peptides were synthesized using solid-phase peptide synthesis (SPPS). Initially, we systematically evaluated the immunogenicity of the synthetic peptides in mice when combined with various adjuvants. The results demonstrated that the Montanide ISA 50Vc adjuvant, in conjunction with the synthetic peptides, elicited the most robust immune response. Building upon this finding, we subsequently formulated the TT-073 and TT-074 synthetic peptide vaccines in varying dosage regimens with Montanide ISA 50Vc adjuvant for swine immunization. Compared to TT-073 synthetic peptide, the TT-074 synthetic peptide exhibited superior immunogenicity. Notably, the high-dose formulation of the TT-074 synthetic peptide induced higher levels of neutralizing antibodies (1:111) while effectively activating both humoral and cellular immune responses, thereby providing robust protection against SVA challenge. This study underscores the immense potential of synthetic biology in vaccine development and provides critical theoretical insights for the future development of synthetic peptide vaccines targeting other pathogens.
2025-09-23ACS Nano
Self-Assembled Nanoparticle Vaccines Elicit Robust Protective Immune Responses against Type O Foot-and-Mouth Disease Virus Infection
Article
作者: Li, Hehai ; Cao, Sheng ; Li, Kun ; Li, Xiangmin ; Qian, Ping ; Yao, Manman ; Diao, Feifei ; Cao, Nan ; Zhang, Huawei ; Rao, Guibo ; Ren, Xujiao ; Lu, Zengjun ; Li, Yamei ; Hu, Zihui ; Tian, Linxing ; Zhao, Qiongqiong
Foot-and-mouth disease virus (FMDV), a critical pathogen in the global livestock industry, has long been a focal point of international disease control strategies. This study developed a nanoparticle-based FMDV vaccine platform. We fused the FMDV immunodominant epitope (VP1-G-H-loop) and T-cell epitope (T3D) with the nanoparticle scaffold lumazine synthase (LS), efficiently producing the T3D-LS-LOOP nanoparticle vaccine using the prokaryotic expression system Escherichia coli (BL21). Mouse experiments showed that the T3D-LS-LOOP nanoparticle vaccine induced a more robust immune response than the LS-LOOP nanoparticle vaccine. To evaluate the role of different scaffolds in FMDV antigen presentation, we substituted the LS scaffold with Ferritin (Ft) and β-annulus peptide (β) nanoparticles, generating T3D-β-LOOP and T3D-Ft-LOOP nanoparticle proteins. The results demonstrated that the LS scaffold-mediated T3D-LS-LOOP nanoparticle vaccine induced the highest neutralizing antibody (NAb) titers (1:28.5) and an effective T-cell immune response, providing 100% protection in mice, outperforming T3D-Ft-LOOP (66.7%) and T3D-β-LOOP (83.3%) nanoparticle vaccines. Encouragingly, the T3D-LS-LOOP nanoparticle vaccine also induced high NAb titers against different lineages (Mya98/Cathay/PanAsia) of type O FMDV and a strong Th2-biased cellular immune response in swine, with no adverse reactions observed postvaccination, achieving complete protection against a type O FMDV challenge in swine.
100 项与 申联生物医药（上海）股份有限公司 相关的药物交易
登录后查看更多信息
100 项与 申联生物医药（上海）股份有限公司 相关的转化医学
登录后查看更多信息
组织架构
使用我们的机构树数据加速您的研究。
登录
或
管线布局
2026年01月23日管线快照
管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期
药物发现
1
登录后查看更多信息
当前项目
登录后查看更多信息
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
营收
使用 Synapse 探索超过 36 万个组织的财务状况。
登录
或
科研基金(NIH)
访问超过 200 万项资助和基金信息，以提升您的研究之旅。
登录
或
投资
深入了解从初创企业到成熟企业的最新公司投资动态。
登录
或
融资
发掘融资趋势以验证和推进您的投资机会。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用